Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 2/20 | 0.49 |
| ▸ | ELANE | P08246 | 10/20 | 0.46 |
| ▸ | CCR1 | P32246 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CTSG | P08311 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | MLX | Q9UH92 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.41 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL1717284 | 0.85 | F2 (0.42) | F2PRSS1TPSAB1ALOX15TSHR | |
| SCHEMBL4412440 | 0.82 | CMA1 (0.46) | ELANECCR1KMT2AALOX15TSHR | |
| Trifluoroacetic Acid SCHEMBL1509589 | 0.81 | XIAP (0.53) | XIAPELANEKMT2ACTSGMLX | |
| Trifluoroacetic Acid SCHEMBL1718165 | 0.81 | XIAP (0.47) | XIAPELANECTSGMLX | |
| Trifluoroacetic Acid SCHEMBL27641390 | 0.81 | XIAP (0.53) | XIAPELANEKMT2ACTSGMLX | |
| SCHEMBL5965048 | 0.78 | FAP (0.43) | F2ALOX15TSHRCASP1 | |
| SCHEMBL7279628 | 0.75 | ELANE (0.50) | ELANECCR1KMT2AF2ALOX15 | |
| SCHEMBL8344533 | 0.74 | MAOB (0.49) | KMT2AALOX15TSHRCASP1 | |
| SCHEMBL8263228 | 0.74 | ACE (0.55) | KMT2AF2PRSS1 | |
| SCHEMBL2769300 | 0.74 | XIAP (0.44) | XIAPELANEKMT2AMLXTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1434792-A2 | PEPTIDYL KETONES AS INHIBITORS OF DPIV | Probiodrug AG (DE) | 2004-07-07 | — | — | EP | claimed |
| US-20030148961-A1 | Peptidyl ketones as inhibitors of DPIV | PROSIDION LIMITED (GB) | 2003-08-07 | — | — | US | claimed |
| WO-2003033524-A2 | PEPTIDYL KETONES AS INHIBITORS OF DPIV | PROBIODRUG AG (DE) | 2003-04-24 | — | — | WO | claimed |
| EP-2338490-A2 | Combinations Useful for the Treatment of Neuronal Disorders | Probiodrug AG (DE) | 2011-06-29 | — | — | EP | disclosed |
| US-7897633-B2 | Neuronal disorders such as Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function; alcoholism | PROBIODRUG AG (DE) | 2011-03-01 | — | — | US | disclosed |
| US-7816325-B2 | Secondary binding site of dipeptidyl peptidase IV (DP IV) | OSI PHARMACEUTICALS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20100159032-A1 | COMBINATIONS USEFUL FOR THE TREATMENT OF NEURONAL DISORDERS | PROBIODRUG AG (DE) | 2010-06-24 | — | — | US | disclosed |
| EP-1620091-B1 | INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2010-03-31 | — | — | EP | disclosed |
| EP-1543023-B1 | SECONDARY BINDING SITE OF DIPEPTIDYL PEPTIDASE IV (DP IV) | PROSIDION LTD (GB) | 2010-03-17 | — | — | EP | disclosed |
| US-7655684-B2 | 1-(Urea-, thiourea- and cyanoguanidine-methylene)benzyl)imidaoles, treatment of neuronal disorders, especially Alzheimer's disease, Down Syndrome, Parkinson's disease and Huntington's disease | PROBIODRUG AG (DE) | 2010-02-02 | — | — | US | disclosed |
| US-7608577-B2 | Peptidyl ketones as inhibitors of DPIV | OSI PHARMACEUTICALS, INC. (US) | 2009-10-27 | — | — | US | disclosed |
| WO-2005075436-A2 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2005-08-18 | — | — | WO | disclosed |
| US-20050176622-A1 | Secondary binding site of dipeptidyl peptidase IV (DPIV) | PROSIDION LIMITED (GB) | 2005-08-11 | — | — | US | disclosed |
| US-20050171112-A1 | Combinations useful for the treatment of neuronal disorders | PROBIODRUG AG | 2005-08-04 | — | — | US | disclosed |
| US-20050137142-A1 | Combinations useful for the treatment of neuronal disorders | PROBIODRUG AG | 2005-06-23 | — | — | US | disclosed |
| EP-1543023-A2 | SECONDARY BINDING SITE OF DIPEPTIDYL PEPTIDASE IV (DP IV) | Prosidion Limited (GB) | 2005-06-22 | — | — | EP | disclosed |
| WO-2005049027-A2 | COMBINATIONS USEFUL FOR THE TREATMENT OF NEURONAL DISORDERS | PROBIODRUG AG (DE) | 2005-06-02 | — | — | WO | disclosed |
| WO-2004098591-A2 | INHIBITORS OF GLUTAMINYL CYCLASE AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES | PROBIODRUG AG (DE) | 2004-11-18 | — | — | WO | disclosed |
| US-20040224875-A1 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2004-11-11 | — | — | US | disclosed |
| WO-2004031374-A2 | SECONDARY BINDING SITE OF DIPEPTIDYL PEPTIDASE IV (DP IV) | PROSIDION LTD. (GB) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171112-A1 | Combinations useful for the treatment of neuronal disorders | MME, DNPEP, DPP4 | XIAP 717/4885ELANE 619/4885CCR1 4508/4885 |
| US-20030148961-A1 | Peptidyl ketones as inhibitors of DPIV | GLS, SLC5A1, BCKDK | XIAP 1058/4885ELANE 1996/4885CCR1 2144/4885 |
| US-20050176622-A1 | Secondary binding site of dipeptidyl peptidase IV (DPIV) | DPP4, DPP3, DPP7 | XIAP 320/4885ELANE 2420/4885CCR1 2308/4885 |
| US-20040224875-A1 | Inhibitors of glutaminyl cyclase | GLS2, GLS, GLUL | XIAP 3488/4885ELANE 4498/4885CCR1 4732/4885 |
| US-20100159032-A1 | COMBINATIONS USEFUL FOR THE TREATMENT OF NEURONAL DISORDERS | MME, DNPEP, DPP4 | XIAP 717/4885ELANE 619/4885CCR1 4508/4885 |
| US-20050137142-A1 | Combinations useful for the treatment of neuronal disorders | MME, DNPEP, DPP4 | XIAP 1827/4885ELANE 621/4885CCR1 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.